Merck's WELIREG Kidney Cancer Trials Deepen Oncology Growth Story [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
Merck (NYSE:MRK) reported new Phase 3 data for belzutifan based WELIREG regimens in renal cell carcinoma, showing meaningful improvements when paired with KEYTRUDA or LENVIMA. The company has filed for FDA reviews that could broaden WELIREG use in both adjuvant and advanced RCC settings, with priority reviews and PDUFA dates set for 2026. These filings and data readouts extend Merck's oncology portfolio beyond its existing blockbusters and introduce new combinations in late stage kidney cancer care. For investors, this update adds another piece to the story around Merck's oncology focus. The company already has a large presence in cancer treatment, and these belzutifan based regimens in RCC further build out that line of business at a time when kidney cancer therapies are seeing active clinical and regulatory work across the industry. From here, the key watchpoints are how the FDA reviews unfold and whether additional regulators outside the US take similar actions. Those deci
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Keytruda's reign continues; pharma's megadeal drought [Yahoo! Finance]Yahoo! Finance
- ????????????????: 2036????????? [CNET News]CNET News
- Merck Price Prediction: Sac-TMT Drug Potential Pushes MRK to $150 [Yahoo! Finance]Yahoo! Finance
- Merck & Co., Inc. (MRK) had its price target raised by Wells Fargo & Company from $135.00 to $150.00. They now have an "overweight" rating on the stock.MarketBeat
- Mestag Therapeutics to Present Data on Targeted LTBR Agonist MST-0312 at Cancer Immunotherapy Keystone Symposia [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 2/3/26 - Beat
MRK
Sec Filings
- 3/12/26 - Form 3
- 2/24/26 - Form 10-K
- 2/17/26 - Form 13F-HR
- MRK's page on the SEC website